|
1
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roodink I and Leenders WP: Targeted
therapies of cancer: Angiogenesis inhibition seems not enough.
Cancer Lett. 299:1–10. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park HE, Baek SH, Min J, Chang YT, Kang
DK, Chang SI and Joe YA: Myoseverin is a potential angiogenesis
inhibitor by inhibiting endothelial cell function and endothelial
progenitor cell differentiation. DNA Cell Biol. 25:514–522. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kretzschmann VK and Furst R: Plant-derived
vascular disrupting agents: Compounds, actions, and clinical
trials. Phytochem Rev. 13:191–206. 2014. View Article : Google Scholar
|
|
5
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Beijnum JR, Dings RP, van der Linden
E, Zwaans BMM, Ramaekers FCS, Mayo KH and Griffioen AW: Gene
expression of tumor angiogenesis dissected: Specific targeting of
colon cancer angiogenic vasculature. Blood. 108:2339–2348. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghilardi C, Chiorino G, Dossi R, Nagy Z,
Giavazzi R and Bani MR: Identification of novel vascular markers
through gene expression profiling of tumor-derived endothelium. BMC
Genomics. 9:2012008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Torijano-Gutiérrez S, Díaz-Oltra S,
Falomir E, Murga J, Carda M and Marco JA: Synthesis of
combretastatin A-4 O-alkyl derivatives and evaluation of their
cytotoxic, antiangiogenic and antitelomerase activity. Bioorg Med
Chem. 21:7263–7274. 2013.
|
|
9
|
Cross MJ and Claesson-Welsh L: FGF and
VEGF function in angiogenesis: Signalling pathways, biological
responses and therapeutic inhibition. Trends Pharmacol Sci.
22:201–207. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Casanovas O, Hicklin DJ, Bergers G and
Hanahan D: Drug resistance by evasion of antiangiogenic targeting
of VEGF signaling in late-stage pancreatic islet tumors. Cancer
Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aalinkeel R, Nair MP, Sufrin G, Mahajan
SD, Chadha KC, Chawda RP and Schwartz SA: Gene expression of
angiogenic factor correlates with metastatic potential of prostate
cancer cells. Cancer Res. 64:5311–5321. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pettit GR, Singh SB, Hamel E, Lin CM,
Alberts DS and Garcia-Kendall D: Isolation and structure of the
strong cell growth and tubulin inhibitor combretastatin A-4.
Experientia. 45:209–211. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krilleke D, DeErkenez A, Schubert W, Giri
I, Robinson GS, Ng YS and Shima DT: Molecular mapping and
functional characterization of the VEGF164 heparin-binding domain.
J Biol Chem. 282:28045–28056. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Parihar S, Kumar A, Chaturvedi AK, Sachan
NK, Luqman S, Changkija B, Manohar M, Prakash O, Chanda D, Khan F,
et al: Synthesis of combretastatin A4 analogues on steroidal
framework and their anti-breast cancer activity. J Steroid Biochem
Mol Biol. 137:332–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Böhle AS, Leuschner I, Kalthoff H and
Henne-Bruns D: Combretastatin A-4 prodrug: A potent inhibitor of
malignant hemangioendothelioma cell proliferation. Int J Cancer.
87:838–843. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Petit I, Karajannis MA, Vincent L, Young
L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E
and Rafii S: The microtubule-targeting agent CA4P regresses
leukemic xenografts by disrupting interaction with vascular cells
and mitochondrial-dependent cell death. Blood. 111:1951–1961. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kremmidiotis G, Leske AF, Lavranos TC,
Beaumont D, Gasic J, Hall A, OCallaghan M, Matthews CA and Flynn B:
BNC105: A novel tubulin polymerization inhibitor that selectively
disrupts tumor vasculature and displays single-agent antitumor
efficacy. Mol Cancer Ther. 9:1562–1573. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khachigian LM and Parish CR:
Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with
clinical potential in multiple vascular pathologies. Cardiovasc
Drug Rev. 22:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Norrby K: Low-molecular-weight heparins
and angiogenesis. APMIS. 114:79–102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bussolati B, Deregibus MC and Camussi G:
Characterization of molecular and functional alterations of tumor
endothelial cells to design anti-angiogenic strategies. Curr Vasc
Pharmacol. 8:220–232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou J, Jin J, Zhang Y, Yin Y, Chen X and
Xu B: Synthesis and antiproliferative evaluation of novel
benzoimidazole-contained oxazole-bridged analogs of combretastatin
A-4. Eur J Med Chem. 68:222–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dark GG, Hill SA, Prise VE, Tozer GM,
Pettit GR and Chaplin DJ: Combretastatin A-4, an agent that
displays potent and selective toxicity toward tumor vasculature.
Cancer Res. 57:1829–1834. 1997.PubMed/NCBI
|
|
23
|
Magalhães HI, Wilke DV, Bezerra DP,
Cavalcanti BC, Rotta R, de Lima DP, Beatriz A, Moraes MO,
Diniz-Filho J and Pessoa C:
(4-Methoxyphenyl)(3,4,5-trimethoxyphenyl) methanone inhibits
tubulin polymerization, induces G2/M arrest, and
triggers apoptosis in human leukemia HL-60 cells. Toxicol Appl
Pharmacol. 272:117–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nathwani SM, Hughes L, Greene LM, Carr M,
OBoyle NM, McDonnell S, Meegan MJ and Zisterer DM: Novel
cis-restricted β-lactam combretastatin A-4 analogues display
anti-vascular and anti-metastatic properties in vitro. Oncol
Rep. 29:585–594. 2013.PubMed/NCBI
|
|
25
|
Nör JE, Christensen J, Liu J, Peters M,
Mooney DJ, Strieter RM and Polverini PJ: Up-regulation of Bcl-2 in
microvascular endothelial cells enhances intratumoral angiogenesis
and accelerates tumor growth. Cancer Res. 61:2183–2188.
2001.PubMed/NCBI
|
|
26
|
Tran J, Master Z, Yu JL, Rak J, Dumont DJ
and Kerbel RS: A role for survivin in chemoresistance of
endothelial cells mediated by VEGF. Proc Natl Acad Sci.
99:4349–4354. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu CJ, Mikami T, Nakamura T, Tsuruta T,
Nakada N, Yanagisawa N, Jiang SX and Okayasu I: Tumor budding,
myofibroblast proliferation and fibrosis in obstructing colon
carcinoma: The roles of Hsp47 and basic fibroblast growth factor.
Pathol Res Pract. 209:69–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Plum SM, Holaday JW, Ruiz A, Madsen JW,
Fogler WE and Fortier AH: Administration of a liposomal FGF-2
peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis
and tumor development. Vaccine. 19:1294–1303. 2001. View Article : Google Scholar
|
